Clinical trials: Nonsmall Cell Lung Cancer, Stage II
Lung Cancer
Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in N2 Positive IIIA Non Small Cell Lung Cancer (NSCLC)
It is suggested that a bimodal or trimodal approach combining neoadjuvant chemotherapy with or without radiotherapy followed by surgery provides a potentially superior method of enhancing resectability and improving locoregional…
- Trial name
- NCT00452803
- Testing
- chemotherapy, Concurrent chemoradiation therapy
- Where
- South Korea
- Volunteers
- 102 people
- Sponsor
- National Cancer Center, Korea
Advanced Cancer, Advanced Solid Tumor
A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients
The study comprises two phases: phase I dose escalation (including PK run-in period and treatment period) and phase II study.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell
- Trial name
- NCT04237805
- Testing
- SAF-189s
- Where
- 41 sites in China
- Volunteers
- 280 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8
The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer
This clinical trial compares the effect of pulmonary vein-first surgical technique to pulmonary artery-first surgical technique in decreasing circulating tumor cell deoxyribonucleic acid (ctDNA) in patients with stage I-III…
- Conditions
- Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
- Trial name
- NCT05502523
- Testing
- Pulmonary Artery-First Surgical Technique, Biospecimen Collection
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- Thomas Jefferson University
Non-Small-Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
The optimal prioritization of second-line chemotherapy and immune therapy based on demographic or biomarker data is an area of ongoing investigation.
- Conditions
- Non-Small-Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent
- Trial name
- NCT02967133
- Testing
- Nivolumab, nab-paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alliance Foundation Trials, LLC.
Non Small Cell Lung Cancer Stage III
Accelerated Radio-Immunotherapy for Lung Cancer
Radiotherapy (RT), at a total dose of 60-66 Gy over 6 weeks, combined with platinum-based chemotherapy, is the standard of care for stage III Non-Small Cell Lung Cancers (NSCLC) patients with unresectable or inoperable disease.
- Trial name
- AIRING (NCT04577638)
- Testing
- Nivolumab and Intensity Modulated Radiotherapy (IMRT)
- Where
- 5 sites in France
- Volunteers
- 8 people
- Sponsor
- Center Eugene Marquis
Lung Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006378
- Testing
- carboplatin, paclitaxel, radiation therapy
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Case Comprehensive Cancer Center
Non-squamous Non-small-cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Study of Crizotinib for ROS1 and MET Activated Lung Cancer
This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has spread to other parts of the body) non-small cell lung cancer with a mutation (change) in genes called ROS1 or MET.
- Conditions
- Non-squamous Non-small-cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, ROS1 Gene Rearrangement, MET Activating Mutation
- Trial name
- NCT04084717
- Testing
- Crizotinib
- Where
- Canada
- Volunteers
- 33 people
- Sponsor
- University Health Network, Toronto
Carcinoma, Non-Small-Cell Lung
Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)
This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected…
- Trial name
- MERMAID-1 (NCT04385368)
- Testing
- Durvalumab + SoC chemotherapy
- Where
- 140 sites in United States, Argentina and 31 more
- Volunteers
- 89 people
- Sponsor
- AstraZeneca
Lung Cancer, Malignant Mesothelioma
Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma
RATIONALE: Vaccines made from a person's tumor may help the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have undergone surgery…
- Trial name
- NCT00003974
- Testing
- lung tumor associated antigen, DetoxPC, chemotherapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Non Small Cell Lung Cancer
Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients
Phase II, single-arm, open-label multicenter study that assesses feasibility, safety and efficacy of combined neoadjuvant chemotherapy and immunotherapy with Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV…
- Trial name
- NCT03081689
- Testing
- Nivolumab 360 mg, Paclitaxel 200mg/m2, Carboplatin AUC 6
- Where
- 24 sites in Spain
- Volunteers
- 46 people
- Sponsor
- Spanish Lung Cancer Group
Stage III Non-small-Cell Lung Cancer
Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC
Resistance of hypoxic tumor cells to radiation is a significant reason of failure in the local control of tumors, especially the squamous cell carcinomas.
- Trial name
- NCT01733589
- Testing
- Recombinant human endostatin, Etoposide (50mg/m2) IV (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cycles, cisplatinum (50mg/m2) IV (in the vein) on day 1 and day 8 of a 28-day cycle for 2 cycles
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Zhejiang Cancer Hospital
NSCLC, Non-small Cell Lung Cancer
Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy
The purpose of this study is to find out whether treatment with the study drug durvalumab combined with a type of radiation therapy called stereotactic body radiation (SBRT) is a more effective treatment for early-stage non-small…
- Conditions
- NSCLC, Non-small Cell Lung Cancer, Lung Cancer, Non-small Cell Lung Cancer Stage I
- Trial name
- NCT04716946
- Testing
- Durvalumab, Stereotactic Body Radiation Therapy
- Where
- 8 sites in United States
- Volunteers
- 13 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
This study is for patients who have Stage IIIb or Stage IV NSCLC and have never had chemotherapy before for their disease. The first phase of the study recently completed and for the second phase of the study patients are…
- Trial name
- NCT00088088
- Testing
- Paclitaxel, Carboplatin, STA 4783
- Where
- 19 sites in United States
- Volunteers
- 86 people
- Sponsor
- Synta Pharmaceuticals Corp.
Lung Cancer
Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00062270
- Testing
- cisplatin, docetaxel, gefitinib
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
Lung Cancer
Chemotherapy Plus Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy used high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003803
- Testing
- cisplatin, gemcitabine hydrochloride, radiation therapy
- Where
- 17 sites in Belgium, France and 3 more
- Volunteers
- 158 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lung Cancer Stage III
Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
The purpose of this study is to studying neoadjuvant IBI308, bevacizumab, plus pemetrexed and carboplatin followed by surgery to see how well it works in treating patients with unresectable stage III non-small cell lung cancer.
- Trial name
- NIBCUN (NCT03872661)
- Testing
- IBI308, Bevacizumab, Pemetrexed
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8
Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer
This phase II trial tests the effect of atezolizumab given with usual chemotherapy during radiation therapy in treating patients with superior sulcus non-small cell lung cancer.
- Conditions
- Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Superior Sulcus Lung Carcinoma
- Trial name
- NCT04989283
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- 46 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations
To assess the efficacy and safety of Almonertinib versus placebo in patients with epidermal growth factor receptor mutation-positive (EGFRm+) stage II-IIIB non-small cell lung cancer (NSCLC), following complete tumor resection…
- Trial name
- NCT04687241
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
The purpose of this multi-center Phase II trial is to examine the impact of pemetrexed/carboplatin in the preoperative treatment of patients with select stage IB, II,and III non-squamous NSCLC.
- Trial name
- NCT00906282
- Testing
- Pemetrexed, Carboplatin
- Where
- 12 sites in United States
- Volunteers
- 46 people
- Sponsor
- SCRI Development Innovations, LLC
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
This phase II clinical trial studies how well combining different regimens of chemotherapy and gefitinib with radiation therapy work in treating patients with stage III non-small cell lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer
- Trial name
- NCT00040794
- Testing
- paclitaxel, carboplatin, gefitinib
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.